Related Experiment Video

Updated: Apr 27, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.2K

MicroRNA-19b functions as potential anti-thrombotic protector in patients with unstable angina by targeting tissue

Sufang Li1, Jingyi Ren1, Ning Xu2

  • 1Department of Cardiology, Peking University People's Hospital, Beijing, China.

Journal of Molecular and Cellular Cardiology
|July 8, 2014
PubMed

Insights

MicroRNAs (miRNAs) regulate hemostatic proteins. In unstable angina (UA) patients, elevated miR-19b in endothelial microparticles (EMPs) may inhibit tissue factor (TF), suggesting an anti-thrombotic role.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Hemostasis Research

Background:

  • Hemostatic system activation is crucial in acute coronary events.
  • MicroRNAs (miRNAs) are implicated in regulating hemostatic proteins.
  • Microparticles (MPs) are key carriers of circulating miRNAs.

Purpose of the Study:

  • To investigate the role of miRNAs in regulating hemostatic gene expression in unstable angina (UA) patients.
  • To identify specific miRNAs involved in the hemostatic system in UA.
  • To explore the relationship between miRNAs, microparticles, and endothelial dysfunction in UA.

Main Methods:

  • MiRNA expression profiling in plasma from UA patients and controls.
  • Real-time PCR validation of miRNA levels in plasma and plasma MPs.
  • Flow cytometry to quantify plasma endothelial microparticles (EMPs).
  • In vitro studies using cultured endothelial cells (ECs) to assess miR-19b release and TF regulation.
  • Bioinformatics and luciferase reporter assays to confirm miR-19b targeting of TF mRNA.

Main Results:

  • miR-19b was identified as a significantly differentially expressed miRNA in UA patients.
  • Plasma EMP levels were elevated in UA patients.
  • TNF-α stimulation increased miR-19b release and expression in ECs.
  • miR-19b directly targets Tissue Factor (TF) mRNA.
  • Overexpression of miR-19b inhibited TF expression and procoagulant activity in ECs.

Conclusions:

  • Elevated miR-19b in EMPs of UA patients, linked to endothelial dysfunction, may contribute to increased circulating miR-19b.
  • miR-19b potentially exerts an anti-thrombotic effect by inhibiting TF expression in endothelial cells.
  • These findings highlight a novel miRNA-mediated regulatory mechanism in the hemostatic system of UA.
Keywords:
Endothelial cellsMicroparticlesThrombosisTissue factorUnstable anginamiRNAs

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

7.9K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
20.9K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K